↓ Skip to main content

Oncotarget

Article Metrics

Management of intracranial melanomas in the era of precision medicine

Overview of attention for article published in Oncotarget, July 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter
4 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
31 Mendeley
Title
Management of intracranial melanomas in the era of precision medicine
Published in
Oncotarget, July 2017
DOI 10.18632/oncotarget.19223
Pubmed ID
Authors

Grace J. Young, Wenya Linda Bi, Winona W. Wu, Tanner M. Johanns, Gavin P. Dunn, Ian F. Dunn

Abstract

Melanoma is the most lethal of skin cancers, in part because of its proclivity for rapid and distant metastasis. It is also potentially the most neurotropic cancer in terms of probability of CNS metastasis from the primary lesion. Despite surgical resection and radiotherapy, prognosis remains guarded for patients with brain metastases. Over the past five years, a new domain of personalized therapy has emerged for advanced melanoma patients with the introduction of BRAF and other MAP kinase pathway inhibitors, immunotherapy, and combinatory therapeutic strategies. By targeting critical cellular signaling pathways and unleashing the adaptive immune response against tumor antigens, a subset of melanoma patients have demonstrated remarkable responses to these treatments. Over time, acquired resistance to these modalities inexorably develops, providing new challenges to overcome. We review the rapidly evolving terrain for intracranial melanoma treatment, address likely and potential mechanisms of resistance, as well as evaluate promising future therapeutic approaches currently under clinical investigation.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 31 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 8 26%
Student > Ph. D. Student 5 16%
Researcher 4 13%
Other 3 10%
Student > Doctoral Student 1 3%
Other 1 3%
Unknown 9 29%
Readers by discipline Count As %
Medicine and Dentistry 9 29%
Biochemistry, Genetics and Molecular Biology 4 13%
Agricultural and Biological Sciences 2 6%
Nursing and Health Professions 1 3%
Physics and Astronomy 1 3%
Other 3 10%
Unknown 11 35%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 July 2021.
All research outputs
#13,385,580
of 21,474,792 outputs
Outputs from Oncotarget
#5,250
of 14,118 outputs
Outputs of similar age
#156,530
of 289,276 outputs
Outputs of similar age from Oncotarget
#441
of 1,352 outputs
Altmetric has tracked 21,474,792 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 14,118 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 289,276 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,352 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.